Wilmington, Delaware, United States, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global hospital infection therapeutics market was estimated to have acquired US$ 11.3 billion in 2022. It is anticipated to register a 2.6% CAGR from 2023 to 2031 and by 2031, the market is likely to gain US$ 14.4 billion.
Advances in regenerative medicine, including the development of tissue engineering and stem cell therapies, may offer novel approaches for treating infections and promoting tissue healing.
Advancements in personalized medicine are expected to lead to the development of infection therapeutic tailored to individual patient profiles, optimizing treatment outcomes.
Download Sample of this Research Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280
Global Hospital Infection Therapeutics Market: Key Players
The following companies are well known participants in the global hospital infection therapeutics market:
- Merck & Co. Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- AstraZeneca
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Allergan plc
- Sanofi S.A.
- Gilead Sciences Inc.
- Basilea Pharmaceutica Ltd.
- Bristol-Myers Squibb Company
Key Findings of the Market Report
- A shift towards patient centric care models emphasizes the importance of preventing and managing infections to improve overall patient outcomes.
- The increasing adoption of telemedicine and remote patient monitoring solutions can contribute to early detection and management of infections, reducing the overall burden on healthcare facilities.
- Integration of data analytics and AI in healthcare can enhance infection surveillance, prediction, and response, leading to more effective therapeutics interventions.
- Shifting healthcare paradigms towards preventive strategies emphasizes the importance of infection prevention, creating opportunities for therapeutics solutions targeting preemptive measures.
Trends for Hospital Infection Therapeutics
- The rise in hospital acquired infections globally has been a significant driver for the hospital infection therapeutics market. Efforts to reduce the incidence of HAIs have led to an increased demand for effective therapeutics solutions.
- Increased awareness among healthcare professionals and the general public regarding the importance of infection prevention has driven the adoption of infection control measures and therapeutics in hospital settings.
- Improvements in healthcare infrastructure, especially in developing regions, contribute to better infection control practices and increased adoption of therapeutics solutions.
- The global issue of antibiotic resistance has highlighted the need for alternative and innovative therapeutics approaches, which has led to the development of new infection control strategies and therapeutics.
Have Any Query? Ask our Experts@ https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=1280
Global Market for Hospital Infection Therapeutics: Regional Outlook
Various reasons are propelling the growth of the hospital infection therapeutics market in different regions. The regions include,
North America
- North America has a robust regulatory framework governing healthcare practices, and stringent standards for infection prevention and control can drive the adoption of therapeutics.
- The high level of healthcare spending in North America, coupled with a focus on patient safety, contributes to investments in infection control measures and therapeutics.
- The implementation of antimicrobial stewardship programs in healthcare facilities promotes the responsible use of antimicrobials, creating opportunities for targeted infection therapeutics.
Asia Pacific
- Asia Pacific is home to regions with a high incidence of infectious diseases, contributing to the demand for effective infection therapeutics in hospitals.
- The sheer size of the population in Asia Pacific countries, combined with a significant healthcare burden, drives the need for infection therapeutics to manage and prevent hospital acquired infections.
Recent Developments
In 2023, Hikma Pharmaceuticals PLC, revealed the introduction of Cefazolin for Injection, USP, available in 2g and 3g doses. The newly launched drug, now available in the United States, serves as a treatment for specific bacterial infections affecting various areas such as the skin, bones, joints, genitals, blood, heart chambers and valves, respiratory tract, biliary tract, and urinary tract. The drug is prescribed for perioperative prophylaxis.
Global Hospital Infection Therapeutics Market Segmentation
Therapeutics
- Anti-Bacterial Drugs
- Anti-Fungal Drugs
- Anti-Viral Drugs
- Others
Infection
- Hospital Acquired Pneumonia
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Surgical Site Infections
- Other Hospital Infections
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Place an Order Copy of the Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=1280<ype=S
Browse More Reports by TMR:
Consumer Genomics Market - The global consumer genomics market was estimated to have acquired US$ 2.4 billion in 2021. It is anticipated to register a 22.3% CAGR from 2022 to 2032 and by 2032, the market is likely to gain US$ 21.2 billion.
Asthma Treatment Market - The global asthma treatment market is projected to flourish at a CAGR of 3.7% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 34.5 billion is anticipated for the market in 2031.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com
